Cellectricon settles patent infringement litigation with Fluxion Cellectricon Stomach and Fluxion Biosciences today announced that they have settled the patent infringement litigation that Cellectricon commenced against Fluxion in ’09 2009.S. Patent Nos sildenafil flashback . 7,390,650, 7,470,518, and 7,563,614. We are very very happy to have achieved a successful conclusion to the litigation, stated David A. Resolution of this lawsuit we can focus on providing innovative and enabling items and discovery solutions for drug discovery and life science research globally. Fluxion couldn't be more happy with the settlement and the results of the litigation..
Ophir Shahaf, CEO of HBL added: We are happy and proud to start to see the company, that was established based on technology developed at Hadassah Medical Organization, develop and grow to the main point where it could aggressively advance its lead product in to the clinic, with the support of the ultimate partners in the field. .. Cell Treat, Teva Pharmaceutical enter permit option contract for OpRegen product BioTime, Inc. , Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Remedy and Teva Pharmaceutical Sectors Ltd. Have entered into an exclusive license option agreement to build up and commercialize Cell Cure’s OpRegenTM item for the treating age-related macular degeneration .